Tcr2 Therapeutics (NASDAQ:TCRR) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Tcr2 Therapeutics and Adverum Biotechnologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tcr2 Therapeutics 0 0 7 0 3.00
Adverum Biotechnologies 0 1 8 0 2.89

Tcr2 Therapeutics presently has a consensus target price of $31.80, indicating a potential upside of 64.85%. Adverum Biotechnologies has a consensus target price of $24.38, indicating a potential upside of 89.69%. Given Adverum Biotechnologies’ higher probable upside, analysts clearly believe Adverum Biotechnologies is more favorable than Tcr2 Therapeutics.

Risk and Volatility

Tcr2 Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.

Earnings and Valuation

This table compares Tcr2 Therapeutics and Adverum Biotechnologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tcr2 Therapeutics N/A N/A -$47.60 million ($4.62) -4.18
Adverum Biotechnologies $250,000.00 4,145.77 -$64.49 million ($1.01) -12.72

Tcr2 Therapeutics has higher earnings, but lower revenue than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Tcr2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tcr2 Therapeutics and Adverum Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tcr2 Therapeutics N/A -38.18% -36.39%
Adverum Biotechnologies N/A -37.66% -31.46%

Insider & Institutional Ownership

45.5% of Tcr2 Therapeutics shares are held by institutional investors. 28.0% of Tcr2 Therapeutics shares are held by insiders. Comparatively, 12.4% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.